Physician profile
Junho Bok Lee
NPI 1245321462
$5,815.02
in general payments reported to CMS, 2019-2025
24 companies · $602 in 2025
The $602 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $858 · 2021: $693 · 2022: $1,022 · 2023: $974 · 2024: $696 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,058.05 | 2019-2025 | |
| Novo Nordisk INC | $891.65 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $731.21 | 2022-2025 | |
| Lilly USA, LLC | $568.05 | 2019-2024 | Mounjaro, Jardiance |
| Amgen INC. | $471.97 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $425.54 | 2020-2025 | Airsupra, Farxiga |
| Amarin Pharma, INC. | $412.82 | 2019-2022 | |
| Gilead Sciences, INC. | $218.82 | 2019-2022 | |
| Astellas Pharma US INC | $179.91 | 2019-2024 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $147.42 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Integra Lifesciences Corporation | $133.34 | 2023 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Merck Sharp & Dohme LLC | $95.15 | 2020-2024 | Gardasil 9, Capvaxive, Gardasil |
| Allergan, INC. | $83.41 | 2019-2020 | |
| Insmed, INC. | $81.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.06 | 2020-2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $59.10 | 2021 | |
| Ironwood Pharmaceuticals, INC | $46.91 | 2023 | Linzess |
| Daiichi Sankyo INC. | $31.12 | 2022 | |
| Sumitomo Pharma America, INC. | $21.43 | 2024 | Gemtesa |
| Phadia US INC. | $20.00 | 2023 | Immunocap |
| Phathom Pharmaceuticals, INC. | $18.72 | 2024 | Voquezna |
| Avanir Pharmaceuticals, INC. | $17.51 | 2019 | |
| Ani Pharmaceuticals, INC. | $16.69 | 2024 | Purified Cortrophin Gel |
| Exact Sciences Corporation | $15.46 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junho Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.